|
|
A new era for CV risk & diabetes management: Treat to earlier, broader and lower targets
|
|
|
|
Global Impact of CVD
|
|
|
|
Heart Protection Study: Impact of Diabetes on CV outcome
|
|
|
|
CVD Accounts for 71% of Costs of Chronic Complications of Diabetes
|
|
|
|
Framingham Heart Study Lifetime Risk
|
|
|
|
High-Normal BP and CVD Risk: Framingham Study
|
|
|
|
Lifetime Atherosclerosis Management
|
|
|
|
UKPDS: Risk Factors for MI.
|
|
|
|
Multiple Risk Factors and CVD Death in Diabetic and Non diabetic Men (MRFIT)
|
|
|
|
Age and CV Risk in Diabetes
|
|
|
|
Benefit of Smoking Cessation
|
|
|
|
13 year old boy weighing 11.2kg more than normal runs 33% increased probability of a cardiovascular event before the age of 60
|
|
|
|
TROPHY Study: ARB in ‘Prehypertension’
|
|
|
|
Drug Treatment in CV Disease
|
|
|
|
RAS and CV Risk
|
|
|
|
Cardiovascular Continuum
|
|
|
|
RAS Blockade, Adipocytes and Diabetes
|
|
|
|
Antioxidant Action of Candesartan
|
|
|
|
CHARM-Overall: New diagnosis of Diabetes
|
|
|
|
RAS Inhibition and New DM
|
|
|
|
Disease modifying treatments
|
|
|
|
Investing in your Arteries! (Big and Little!)
|
|
|
|
BP Treatment in Type 2 DM
|
|
Share this page with your colleagues and friends: